The local sensitizing patterns for allergic rhinitis (AR) vary globally, while house dust mite (HDM) was a common aeroallergen responsible, causing perennial nasal symptoms. The efficacies of AR are evaluated by assessing changes in individual and total nasal symptom score by means of visual analogue scale, medication score, and quality of life (QoL) using rhinoconjunctivitis quality of life questionnaire (RQLQ), following treatment. The safety profile is usually assessed as incidence or prevalence of adverse effects (AEs). Allergen specific immunotherapy (AIT), including subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT), is the only etiological treatment available for AR, while selective immunomodulator is also available for perennial allergic rhinitis (PAR). There are relatively few AIT trials on HDM-induced AR, and although it is not clear whether SCIT or SLIT is better in this respect, while promising evidence of efficacy for SLIT has been confirmed. To our knowledge, no meta-analysis has been reported of SCIT for HDM-induced PAR. Thus, we performed a meta-analysis of appropriate studies studying the efficacy and safety of HDM-SCIT in patients with HDM-induced PAR.